利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.037 秒)

    PHARMACEUTICAL COMPOSITION CONTAINING THE NMB0938 PROTEIN
    2.
    发明申请
    PHARMACEUTICAL COMPOSITION CONTAINING THE NMB0938 PROTEIN 审中-公开
    含有NMB0938蛋白的药物组合物

    公开(公告)号：US20090297547A1

    公开(公告)日：2009-12-03

    申请号：US12295436

    申请日：2007-03-29

    申请人： Rolando Pajon Feyt ,  Gretel Sardinas Garcia ,  Darien Garcia Diaz ,  Sonia Gonzalez Blanco

    发明人： Rolando Pajon Feyt ,  Gretel Sardinas Garcia ,  Darien Garcia Diaz ,  Sonia Gonzalez Blanco

    IPC分类号： A61K39/12 ,  C12Q1/68 ,  G01N33/53 ,  A61K38/16 ,  C07K14/22

    CPC分类号： A61K39/095 ,  A61K2039/6068 ,  C07K14/22

    摘要： The present invention is related to field of medicine, particularly to the development of pharmaceutical formulation containing NMB0938 protein. Formulation described in this invention is able to confer protection against different diseases caused or not by pathogenic agents. NMB0938 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation the NMB0938 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. Formulation presented in this invention is applicable to the field of human medicine.

    摘要翻译： 本发明涉及药物领域，特别涉及含有NMB0938蛋白质的药物制剂的开发。 本发明描述的制剂能够赋予针对由病原体引起或不由病原体引起的不同疾病的保护作用。 NMB0938蛋白被鉴定为脑膜炎奈瑟氏球菌外膜囊泡（OMV）组分，通过重组DNA技术获得其在动物模型中评估的免疫原性和保护活性。 由于NMB0938编码基因的保守程度高，含有这种蛋白质的药物组合物具有高价值作为交叉反应性免疫应答的诱导剂。 本发明提出的制剂适用于人类医学领域。

    Protein Nmb1125 and Use Thereof in Pharmaceutical Formulations
    5.
    发明申请
    Protein Nmb1125 and Use Thereof in Pharmaceutical Formulations 失效
    蛋白质Nmb1125及其在药物制剂中的应用

    公开(公告)号：US20070218000A1

    公开(公告)日：2007-09-20

    申请号：US10580508

    申请日：2004-12-02

    申请人： Rolando Feyt ,  Enrique Gerardo ,  Gretel Sardinas Garcia ,  Nunez Lazaro Betancourt ,  Serra Castellanos ,  Negrin Perera ,  Diaz Garcia ,  Perez Niebla ,  Menendez Caballero ,  Blanco Gonzalez

    发明人： Rolando Feyt ,  Enrique Gerardo ,  Gretel Sardinas Garcia ,  Nunez Lazaro Betancourt ,  Serra Castellanos ,  Negrin Perera ,  Diaz Garcia ,  Perez Niebla ,  Menendez Caballero ,  Blanco Gonzalez

    IPC分类号： A61K39/02 ,  A61K39/00 ,  A61K49/00 ,  C07K14/00 ,  C12N1/00 ,  C12Q1/68 ,  G01N33/53

    CPC分类号： C07K14/22 ,  A61K39/00 ,  A61K2039/523 ,  A61K2039/53

    摘要： Use of a novel vaccine antigen applied in a preventive or therapeutic way against diseases in general, being such disease of bacterial, viral, cancer related, or other origin. The technical objective that this invention pursues is the development of formulations with the ability to increase the protective spectrum of existing vaccines and hence expanding it against different pathogens. In order to achieve this goal the NMB1125 protein was isolated and identified as a component of outer membrane preparations of Neisseria meningitidis capable of inducing bactericidal activity. Additionally, the gene codifying for NMB1125 protein was cloned and expressed, and the said polypeptide was purified and its immunogenicity evaluated in animal models. The sequence data from homologous genes showed, due to the high degree of conservation, its high value as a target antigen of a cross-reactive response when it is presented by different routes. Resultant formulations of this invention are of use in the pharmaceutical industry as vaccine formulations for human use.

    摘要翻译： 使用以预防或治疗方式应用的新型疫苗抗原，通常可以防止一般疾病，这些细菌，病毒，癌症相关或其它来源的疾病。 本发明所追求的技术目标是开发具有增加现有疫苗的保护性能并因此扩增其抵抗不同病原体的能力的制剂。 为了达到这个目标，NMB1125蛋白被分离并鉴定为能够诱导杀菌活性的脑膜炎奈瑟氏球菌外膜制剂的组分。 另外，克隆和表达编码NMB1125蛋白的基因，并且将所述多肽纯化，并在动物模型中评估其免疫原性。 来自同源基因的序列数据显示，由于高度的保守性，当通过不同途径呈现时，其作为交叉反应性应答的靶抗原的高值显示出来。 本发明的所得制剂在制药工业中用作人类使用的疫苗制剂。